Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 3, 2014, Pages 539-549

  Sausville, Edward ^a   LoRusso, Patricia ^b   Carducci, Michael ^c   Carter, Judith ^a   Quinn, Mary F ^a   Malburg, Lisa ^b   Azad, Nilofer ^c   Cosgrove, David ^c   Knight, Richard ^d   Barker, Peter ^d   Zabludoff, Sonya ^d   Agbo, Felix ^d   Oakes, Patricia ^d   Senderowicz, Adrian ^d  

^a UNIVERSITY OF MARYLAND   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

AZD7762; Chk1; Pharmacokinetics; Phase I; Safety; Solid tumors

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GEMCITABINE; HEMOGLOBIN; TROPONIN I;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; COUGHING; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DEHYDRATION; DEVICE INFECTION; DIARRHEA; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENDOCARDITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLANK PAIN; HEART ATRIUM THROMBOSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOPENIA; LIMB PAIN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; OCCLUSION; OPEN STUDY; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; SINGLE DRUG DOSE; SMALL INTESTINE OBSTRUCTION; SOLID TUMOR; THORAX PAIN; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNITED STATES; UPPER GASTROINTESTINAL BLEEDING; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASES; THIOPHENES; UREA;

EID: 84896031764     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2380-5     Document Type: Article

References (28)

1. Weinert TA, Hartwell LH (1988) The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 241:317-322
2. Hartwell LH, Weinert TA (1989) Checkpoints: controls that ensure the order of cell cycle events. Science 246:629-634 (Pubitemid 19283354)
3. Wahl GM, Linke SP, Paulson TG, Huang LC (1997) Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv 29:183-219 (Pubitemid 27262247)
4. Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15:2177-2196
5. Zinkel S, Gross A, Yang E (2006) BCL2 family in DNA damage and cell cycle control. Cell Death Differ 13:1351-1359 (Pubitemid 44057470)
6. Lau CC, Pardee AB (1982) Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA 79:2942-2946 (Pubitemid 12032347)
7. Sausville EA, Johnson J, Alley M, Zaharevitz D, Senderowicz AM (2000) Inhibition of CDKs as a therapeutic modality. Ann N Y Acad Sci 910:207-221
8. Shapiro GI, Harper JW (1999) Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104:1645-1653 (Pubitemid 30053178)
9. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA (1995) Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 6:927-936
10. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H (2000) The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275:5600-5605 (Pubitemid 30115197)
11. Zhao B, Bower MJ, McDevitt PJ, Zhao H, Davis ST, Johanson KO, Green SM, Concha NO, Zhou BB (2002) Structural basis for Chk1 inhibition by UCN-01. J Biol Chem 277:46609-46615 (Pubitemid 35417660)
12. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM (1996) UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88:956-965 (Pubitemid 26239383)
13. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S (1998) Unpredicted clinical pharmacology of UCN- 01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 58:3248-3253 (Pubitemid 28371060)
14. Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM (2001) Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19:2319-2333 (Pubitemid 32366984)
15. Sato S, Fujita N, Tsuruo T (2002) Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21:1727-1738 (Pubitemid 34259036)
16. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 7:2955-2966
17. Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff Z, Cook JA (2010) In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 16:2076-2084
18. AstraZeneca (2011) Global policy: bioethics. http://www.astrazeneca.com/ Responsibility/Code-policies-standards/ Our-global-policies
19. Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications, 3rd edn. Lippincott, Williams and Wilkins, Philadelphia, USA
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
21. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, Canman CE, Normolle DP, Zabludoff SD, Maybaum J, Lawrence TS (2010) Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 70:4972-4981
22. Ho AL, Bendell JC, Cleary JM, Schwartz GK, Burris HA, Oakes P, Agbo F, Barker PN, Senderowicz AM, Shapiro G (2011) Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors. J Clin Oncol 29(15S):abst 3033
23. Seto T, Esaki T, Hirai T, Arita S, Nosaki K, Makiyama A, Kometani T, Fujimoto C, Hamatake M, Takeoka H, Agbo F, Shi X (2013) Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 72:619-627
24. Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T, Ikeda K, Nakayama K, Nakanishi M, Nakayama K (2000) Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev 14:1439-1447 (Pubitemid 30421837)
25. Erickson JR, He BJ, Grumbach IM, Anderson ME (2011) CaMKII in the cardiovascular system: sensing redox states. Physiol Rev 91:889-915
26. +-ATPase is critical for skeletal and heart muscle function in zebrafish. J Cell Sci 125:6166-6175
27. Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten K, Peterson KL, Schneider P, Mackey K, Freshwater T, Levis M, McDevitt M, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Issacs R, Kaufmann SH (2012) Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor SCH 900776 in refractory acute leukemias. Clin Cancer Res 18:6723-6731
28. Depamphilis ML, de Renty CM, Ullah Z, Lee CY (2012) "The Octet": eight protein kinases that control mammalian DNA replication. Front Physiol 3:368